Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)‘s stock had its “hold” rating reiterated by equities researchers at J P Morgan Chase & Co in a note issued to investors on Thursday. They presently have a $14.00 price target on the biotechnology company’s stock. J P Morgan Chase & Co’s price target points to a potential upside of 8.32% from the company’s current price.

MNTA has been the topic of several other research reports. Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They issued a “neutral” rating and a $18.00 target price on the stock. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Maxim Group set a $6.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “sell” rating in a research note on Thursday, August 3rd. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $15.00 target price (down previously from $22.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. Momenta Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $15.00.

Momenta Pharmaceuticals (NASDAQ MNTA) opened at 12.95 on Thursday. The company’s market cap is $959.03 million. The company has a 50-day moving average of $16.69 and a 200 day moving average of $15.79. Momenta Pharmaceuticals has a 12 month low of $10.75 and a 12 month high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The firm had revenue of $23.57 million for the quarter, compared to the consensus estimate of $24.64 million. Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business’s revenue was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.31) earnings per share. On average, equities analysts forecast that Momenta Pharmaceuticals will post ($1.53) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) Rating Reiterated by J P Morgan Chase & Co” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/07/momenta-pharmaceuticals-inc-mnta-rating-reiterated-by-j-p-morgan-chase-co.html.

In related news, President Craig A. Wheeler sold 4,116 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now owns 269,231 shares in the company, valued at $4,057,311.17. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Craig A. Wheeler sold 35,667 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the transaction, the president now owns 286,121 shares in the company, valued at approximately $5,444,882.63. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,663 shares of company stock worth $1,414,498. 4.40% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of MNTA. Ameritas Investment Partners Inc. lifted its position in Momenta Pharmaceuticals by 14.9% during the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 834 shares during the period. Tortoise Investment Management LLC bought a new position in Momenta Pharmaceuticals during the second quarter valued at approximately $114,000. Pinebridge Investments L.P. lifted its position in Momenta Pharmaceuticals by 4.3% during the second quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 363 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Momenta Pharmaceuticals during the first quarter valued at approximately $158,000. Finally, BNP Paribas Arbitrage SA lifted its position in Momenta Pharmaceuticals by 13.3% during the first quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 1,570 shares during the period. Institutional investors own 93.86% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.